ClinicalTrials.gg
RecruitingNCT07508761Updated Jun 29, 2026

IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors

A Phase 1/2 interventional study of IPG7236 and Toripalimab Injection in Advanced Solid Tumor, sponsored by Nanjing Immunophage Biotech Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by Nanjing Immunophage Biotech Co., Ltd · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
52
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Phase 1/2 Study for IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors

Read the detailed description

This is a phase 1/2, multicenter, non-randomized, open-label, dose-escalation and dose-expansion study. Part A (dose escalation) will adopt a standard "3+3" design with two cohorts (IPG7236 500 mg BID + Toripalimab 240 mg Q3W; IPG7236 800 mg BID + Toripalimab 240 mg Q3W) to determine the MTD and/or RP2D. Part B (dose expansion) will enroll approximately 40 CCR8-positive advanced solid tumor patients to further evaluate safety,tolerability and preliminary antitumor activity. The transition from Part A to Part B will be triggered after confirmation of RP2D based on safety, tolerability, PK and preliminary efficacy data.

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

Nanjing Immunophage Biotech Co., Ltd is the lead sponsor of 11 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written must be obtained before any study procedure is performed.
  2. Men or women 18 years of age or older.
  3. or cytologically confirmed advanced or recurrent malignant solid tumors that are or unresectable. (Subjects must submit tumor tissue sections from within the past 5 years for CCR8 expression testing. For subjects without paraffin-embedded tissues, a fine-needle aspiration may be performed. Subjects who cannot provide tumor tissue sections or undergo biopsy are only eligible for inclusion during the dose escalation phase. During the dose expansion phase, CCR8 positivity must be known or tumor tissue sections must be provided with confirmed CCR8 expression.)
  4. Subjects must have failed or been intolerant to standard antitumor therapy, or lack a standard treatment regimen, or be deemed by the investigator as currently unsuitable for standard therapy.
  5. According to the 1.1 criteria, there is at least one .
  6. ≥ 3 months.
  7. Subjects must be able to swallow the oral drug.
  8. The performance status score is 0 or 1.
  9. Sufficient hematologic and organ function, with the following laboratory test values:

    1. Hematology: (ANC) ≥ 1.5×10⁹/L; count ≥ 75×10⁹/L; ≥ 9 g/dL; lymphocytes ≥ 0.8×10⁹/L;
    2. Renal: calculated by the Cockcroft-Gault method ≥ 50 mL/min or serum creatinine ≤ 1.5× (ULN);
    3. Hepatic: (AST) and Alanine aminotransferase (ALT) ≤ 3×ULN, or ≤ 5×ULN for subjects with liver metastases; total ≤ 1.5×ULN, or ≤ 3×ULN for subjects with Gilbert syndrome or genetically equivalent conditions;
    4. Coagulation: (PT) and activated partial thromboplastin time (aPTT) ≤ 1.5× upper limit of normal (ULN).
  10. Patients must be willing and able to comply with all scheduled visits, treatments, laboratory tests, and other study requirements.
  11. Male and female participants of who engage in heterosexual sexual behavior must agree to use reliable methods (hormonal, barrier, or abstinence,etc.) for at least 4 months during the trial period and after the last study drug administration (refer to Appendix 13.1 of the protocol)

Exclusion criteria

Exclusion Criteria:

  1. Primary malignant tumors of the central nervous system or malignant tumors associated with (HIV) .
  2. Previous use of CCR8-targeted therapy.
  3. Received the following treatment within the specified time frame:

    1. Planned major surgery within 4 weeks prior to the first dose administration (excluding minor procedures such as vascular access placement, gastrointestinal/biliary stent placement, or );
    2. Immunotherapy or biological therapy administered within 28 days prior to the initial administration;
    3. Chemotherapy \<21 days prior to the first dose, or mitomycin or nitrosoureas \< 42 days prior, or oral fluoropyrimidines \< 14 days prior;
    4. Targeted small-molecule therapy or traditional Chinese medicine with antitumor indications administered within 14 days prior to the initial dose;
    5. Hormone therapy or other therapies are not permitted if initiated within 14 days prior to the first dose. Exceptions: anti-estrogen therapy, bisphosphonates, RANKL monoclonal antibodies, somatostatin analogs, and leuprorelin are permitted if initiated ≥ 14 days prior to the first dose.
    6. Radiotherapy administered within 28 days prior to the first dose, or palliative radiotherapy within 14 days prior. Exception: Palliative radiotherapy (e.g., for analgesia) may be performed during the study drug administration period, provided that it is not permitted during the DLT observation period, any previously induced adverse events from radiotherapy have been resolved to grade \<2, and the radiotherapy was not directed at the target lesion.
    7. Other or treatments administered within 28 days prior to the first dose;
    8. Any previous allogeneic tissue/solid organ transplantation, including stem cell transplantation;
  4. Previous treatment-related toxicity has not yet resolved to a level of ≤ 1 per National Cancer Institute (NCI) (CTCAE) v6.0 or to the specified levels in the inclusion/exclusion criteria (except for safety risks deemed by the investigator as not significant, such as alopecia, grade 2 peripheral neuropathy, hypothyroidism or hyperthyroidism, or other endocrine disorders well-controlled by hormone replacement therapy).
  5. In combination with other active (excluding basal cell carcinoma of the skin, cervical carcinoma in situ, or superficial bladder cancer with no evidence of disease after potentially curative treatment; For other patients with previous malignant tumors who have survived without disease for more than 3 years, they are also (acceptable).
  6. Immune-related adverse events (irAEs) of grade ≥ 3 or those leading to treatment discontinuation during prior immunotherapy, or grade ≥ 2 immune-mediated myocarditis, or treatment discontinuation due to allergic or infusion-related reactions.
  7. Diagnosis of primary or acquired immunodeficiency, or receipt of systemic or any other form of therapy within 7 days prior to the first dose. Exceptions: intraocular, intranasal, intra-articular, inhaled, or systemic glucocorticoids (prednisone dose ≤ 10 mg/day or equivalent, or doses used for adrenal replacement therapy), as well as a single dose of immunosuppressive medication for contrast agent allergy prophylaxis (if no active disease is present).
  8. History of autoimmune disease requiring systemic therapy or active autoimmune diseases (i.e., requiring glucocorticoids or immunosuppressive agents for disease control) within 2 years prior to study initiation are eligible, provided they do not require immunosuppressive therapy for conditions such as type 1 diabetes mellitus, vitiligo, psoriasis,hypothyroidism, or hyperthyroidism.
  9. Known severe or life-threatening allergic reactions to humanized monoclonal antibodies (mAbs) or intravenous immunoglobulin (Ig) preparations; known to any investigational drug, its analogues, or .
  10. Untreated , meningeal , or spinal cord compression not definitively treated with surgery or radiotherapy. (Patients with brain metastases who have stabilized without symptoms after prior treatment and have not received high-dose steroid therapy are eligible for enrollment.)
  11. Uncontrolled or requiring intravenous anti-infective therapy for active bacterial, fungal, or viral infections.
  12. Active virus (HBV) and/or virus (HCV) and/or HIV:

    1. Participants must be negative for hepatitis B surface antigen (HBsAg).
    2. For HCV antibody-positive subjects, the HCV RNA quantification must be below the research center's detection limit.
    3. HIV test must be negative at screening;
  13. Administration of live or within 4 weeks prior to the first dose (inactivated vaccines, viral vector vaccines, and mRNA vaccines are permitted; seasonal vaccines should be completed prior to the first dose).
  14. The serum pregnancy test is positive within 3 days before the first dose.
  15. Lactating female subjects.
  16. Pneumonitis, interstitial lung disease, or severe radiation pneumonitis (excluding localized radiation pneumonitis) requiring glucocorticoid therapy.
  17. Patients with clinically uncontrollable ascites or pleural effusion are deemed unsuitable for enrollment by the investigator.
  18. Symptomatic cardiovascular or cerebrovascular disease; accident/stroke or myocardial infarction (MI), unstable angina, congestive heart failure ( class III or higher), or severe arrhythmias uncontrolled by pharmacotherapy within 6 months prior to enrollment; mean corrected for heart rate using the Fridericia formula (QTcF) ≥ 470 ms.
  19. Any medical or social condition that may expose subjects to higher risks, affect compliance, or obscure the interpretation of safety or other clinical study data
Terms in these criteria, in plain language(35)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (estimated)

Study arms

  • Experimental
    Part A(Cohort 1) :IPG7236 500mg & Toripalimab

    3-6 subjects in this cohort will receive IPG7236 500 mg BID and Toripalimab Injection 240 mg, Dose-escalation cohort with 3+3 design; DLT assessment period is 21 days.

    Drug: IPG7236 · Drug: Toripalimab Injection

  • Experimental
    Part A(Cohort 2):IPG7236 800mg& Toripalimab

    3-6 subjects in this cohort will receive IPG7236 800 mg BID and Toripalimab Injection 240 mg,Dose-escalation cohort with 3+3 design; enrolled sequentially after Cohort 1; DLT assessment period is 21 days.

    Drug: IPG7236 · Drug: Toripalimab Injection

  • Experimental
    Part B:IPG7236 RP2D & Toripalimab

    40 subjects in this cohort will receive IPG7236 at the RP2D BID and Toripalimab Injection 240 mg

    Drug: IPG7236 · Drug: Toripalimab Injection

Interventions

  • DrugIPG7236

    Drug pages: IPG-7236 · CCR8 Inhibitor IPG7236

    IPG7236: Part A: 500 mg BID or 800 mg BID, the dose in Part B is the RP2D confirmed in Part A, Oral (fasting: 1 hour before meal or 2 hours after meal, every 12±2 hours), Continuous daily administration, 21-day treatment cycle,Until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons for withdrawal

  • Toripalimab Injection: 240 mg , Q3W, 21-day treatment cycle, the first infusion lasts at least 60 minutes; if well tolerated, subsequent infusions can be shortened to 30 minutes.

06

What researchers measure

Primary outcomes

  1. Incidence of Dose-Limiting Toxicity (DLT)

    Dose-Limiting Toxicity (DLT) is treatment-related adverse events (excluding disease progression/external causes) per NCI CTCAE v6.0, occurring within Cycle 1 Day 1-21,1) Unexplained death; 2) Hematological: Grade 4 neutropenia \>7d; Grade ≥3 febrile neutropenia; Grade 4 thrombocytopenia or Grade 3 with clinical bleeding; Grade 4 anemia; 3) Non-hematological: Grade ≥3 (exceptions: Grade 3 nausea/vomiting/diarrhea \<3d with antiemetics; Grade 3 fatigue \<1w; pancreatitis-unrelated Grade ≥3 amylase/lipase; Grade ≥3 electrolyte disturbance resolving within 72h without complications; asymptomatic isolated lab abnormalities); Hepatotoxicity: Hy's Law (ALT/AST \>3×ULN + total bilirubin \>2×ULN + ALP \<2×ULN); AST/ALT \>8×ULN (or \>8×baseline for liver metastasis); AST/ALT \>5×ULN (or \>5×baseline for liver metastasis) ≥14d; Other Grade 4 non-hematological toxicity; 4) Toxicity requiring permanent study drug discontinuation or \<75% planned administration. Infusion-related reactions are not DLT;

    Time frame: Up to 21 days after first dose (Cycle 1): To determine the DLT according to NCI CTCAE v6.0, and define the Maximum Tolerated Dose (MTD) and RP2D of IPG7236 in combination with toripalimab

  2. Percentage of patients with adverse events

    Time frame: From first dose to 90 days after last dose or initiation of new anti-cancer therapy, whichever comes first

Secondary outcomes

  1. Objective Response Rate (ORR) per iRECIST v1.1

    Objective Response Rate (ORR) is defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR) per iRECIST v1.1 criteria.

    Time frame: From first dose to disease progression or death (up to 24 months)

  2. Disease Control Rate (DCR) per iRECIST v1.1

    Disease Control Rate (DCR) is defined as the percentage of participants with a best overall response of complete response (CR), partial response (PR), or stable disease (SD) per iRECIST v1.1 criteria.

    Time frame: From first dose to disease progression or death (up to 24 months)

  3. Duration of Response (DoR) per iRECIST v1.1

    Duration of Response (DoR) is defined as the time from first documentation of objective response (CR or PR) to first documentation of progressive disease (PD) or death due to any cause, per iRECIST v1.1 criteria.

    Time frame: From first documentation of objective response (CR or PR) to first documentation of progressive disease (PD) or death (up to 24 months)

  4. Progression-Free Survival (PFS) per iRECIST v1.1

    Progression-Free Survival (PFS) is defined as the time from first dose to first documentation of progressive disease (PD) per iRECIST v1.1 criteria or death due to any cause, whichever occurs first.

    Time frame: From first dose to disease progression or death (up to 24 months)

  5. Overall Survival (OS) per iRECIST v1.1

    Overall Survival (OS) is defined as the time from first dose to death due to any cause.

    Time frame: From first dose to death due to any cause (up to 24 months)

  6. Peak Plasma Concentration (Cmax) of IPG7236

    Peak plasma concentration of IPG7236, determined from plasma concentration-time profiles obtained at preset time points.

    Time frame: From first dose to end of treatment, assessed up to 24 months

  7. Trough Plasma Concentration (Cmin) of IPG7236

    Trough plasma concentration of IPG7236, determined from plasma concentration-time profiles obtained at preset time points.

    Time frame: From first dose to end of treatment, assessed up to 24 months

  8. Area Under the Plasma Concentration-Time Curve (AUC) of IPG7236

    Area under the plasma concentration-time curve of IPG7236, calculated using non-compartmental analysis from plasma samples collected at preset time points.

    Time frame: From first dose to end of treatment, assessed up to 24 months

  9. Time to Peak Plasma Concentration (Tmax) of IPG7236

    Time to reach peak plasma concentration of IPG7236, determined from plasma concentration-time profiles obtained at preset time points.

    Time frame: From first dose to end of treatment, assessed up to 24 months

  10. Elimination Half-Life (T1/2) of IPG7236

    Elimination half-life of IPG7236, calculated from the terminal phase of the plasma concentration-time curve obtained at preset time points.

    Time frame: From first dose to end of treatment, assessed up to 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Dec 2028, 30 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2026
First posted
Apr 2, 2026
StartActual
Jun 16, 2026
Primary completionEst.
Dec 30, 2028
CompletionEst.
Jul 30, 2029
Last update
Jun 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07508761
Lead sponsor
Nanjing Immunophage Biotech Co., Ltd
Responsible party
Sponsor
First posted
Apr 2, 2026
Start date
Jun 16, 2026
Primary completion
Dec 30, 2028 (estimated)
Completion
Jul 30, 2029 (estimated)
Last update
Jun 29, 2026

Study contacts

jian fei wang, CSO
Contact
jfwang@immunophage.com.cn
+86-21-34782827

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: IPG-7236 · CCR8 Inhibitor IPG7236

Start the discussion